Close Menu

More articles about Liquid Biopsy

The company plans to expand its CLIA testing and complete a major study in theUS, as it moves forward to open a joint venture inChinathat will support further commercial expansion and clinical utility research.

The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples.

The firm will use the financing to support clinical development and commercialization of its CTC and ctDNA liquid biopsy technology.

The company plans to move away from a centralized lab model to develop kits that can be used by any laboratory to perform its assays, focusing first on developing RUO kits and then clinical assay for lung cancer and more.

The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform. 

The group used next-generation sequencing and droplet-digital PCR blood-based assays to monitor resistance mutations in colorectal cancer patients.

The partners will explore the use of Biocept's liquid biopsy technology to identify and detect biomarkers in ER-positive breast cancer patients.

Researchers and commercial vendors highlighted new data and clinical utility, but also discussed challenges in validating and establishing liquid biopsy diagnostics.

The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.

With the certification, Resolution can offer its test to researchers and clinicians to help guide personalized therapies and direct patients into clinical trials.

Angle Parsortix platform

UK firm Angle is increasing its focus on the women's health arena as it seeks to push its flagship Parsortix cell separation system into clinical use.

The firm saw its revenues more than quadruple year over year to $150,000, mainly due to expansion of its commercial liquid biopsy testing business.

During a conference call, management discussed new commercial initiatives and investments, reimbursement progress, and its partnership with Roche.

The company is developing liquid biopsy tests to detect disease recurrence and drug resistance, but does not yet have a specific plan for its first commercial assay.

The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.

Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.

The StrandAdvantage test currently analyzes 48 cancer-related genes on one of the laboratory's three Illumina MiSeq instruments.

With the support of the new funds, the company hopes to launch its NeoLiquid test by the end of this year after completing beta tests.


New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.